Merge branch 'main' into extract/2025-11-00-sahoo-rlhf-alignment-trilemma
This commit is contained in:
commit
b840f82b67
15 changed files with 182 additions and 106 deletions
|
|
@ -49,16 +49,28 @@ The BALANCE Model directly addresses the chronic use inflation problem by requir
|
|||
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2025-01-01-select-cost-effectiveness-analysis-obesity-cvd]] | Added: 2026-03-16*
|
||||
*Source: 2025-01-01-select-cost-effectiveness-analysis-obesity-cvd | Added: 2026-03-16*
|
||||
|
||||
At net prices with 48% rebates, semaglutide achieves $32,219/QALY ICER, making it highly cost-effective. The Trump Medicare deal at $245/month (82% discount) would push ICER below $30K/QALY. The inflationary claim may need scope qualification: GLP-1s are inflationary at list prices but potentially cost-saving at negotiated net prices, and the price trajectory is declining faster than the 2035 projection anticipated.
|
||||
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16*
|
||||
*Source: 2025-11-06-trump-novo-lilly-glp1-price-deals-medicare | Added: 2026-03-16*
|
||||
|
||||
The Trump Administration's Medicare GLP-1 deal establishes $245/month pricing (82% below list) with narrow eligibility criteria requiring comorbidities (BMI ≥27 with prediabetes/CVD or BMI >30 with heart failure/hypertension/CKD). This targets ~10% of Medicare beneficiaries—specifically the high-risk population where downstream savings (24% kidney disease progression reduction, cardiovascular protection) offset drug costs under capitation. The narrow eligibility is the mechanism that changes the cost-effectiveness calculus: inflationary impact depends on population breadth, not just drug price.
|
||||
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-16*
|
||||
|
||||
The sarcopenic obesity mechanism creates a pathway where GLP-1s may INCREASE healthcare costs in elderly populations: muscle loss during treatment + high discontinuation (64.8% at 1 year) + preferential fat regain = sarcopenic obesity → increased fall risk, fractures, disability, and long-term care needs. This directly challenges the Medicare cost-savings thesis by creating NEW healthcare costs (disability, falls, fractures) that may offset cardiovascular and metabolic savings.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-12-01-who-glp1-global-guidelines-obesity]] | Added: 2026-03-16*
|
||||
|
||||
WHO issued conditional recommendations (not full endorsements) for GLP-1s in obesity treatment, explicitly acknowledging 'limited long-term evidence.' The conditional framing signals institutional uncertainty about durability of outcomes and cost-effectiveness at population scale. WHO requires countries to 'consider local cost-effectiveness, budget impact, and ethical implications' before adoption, suggesting the chronic use economics remain unproven for resource-constrained health systems.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -49,10 +49,16 @@ No data yet on whether payment model affects persistence—does being in an MA p
|
|||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16*
|
||||
*Source: 2025-11-06-trump-novo-lilly-glp1-price-deals-medicare | Added: 2026-03-16*
|
||||
|
||||
The $50/month out-of-pocket maximum for Medicare beneficiaries (starting April 2026 for tirzepatide) removes most financial barriers to persistence for the eligible population. Lower-income patients show higher discontinuation rates, suggesting affordability drives persistence. The OOP cap may improve persistence rates specifically in Medicare, though this remains untested.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-16*
|
||||
|
||||
The discontinuation problem is worse than just lost metabolic benefits - it creates a body composition trap. Patients who discontinue lose 15-40% of weight as lean mass during treatment, then regain weight preferentially as fat without muscle recovery. This means the most common outcome (discontinuation) leaves patients with WORSE body composition than baseline: same or higher fat, less muscle, higher disability risk. Weight cycling on GLP-1s is not neutral - it's actively harmful.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -41,6 +41,12 @@ The Commonwealth Fund's 2024 Mirror Mirror international comparison provides the
|
|||
|
||||
The NHS paradox—ranking 3rd overall while having catastrophic specialty access—provides supporting evidence that medical care's contribution to health outcomes is limited. A system can have multi-year waits for specialty procedures yet still rank highly in overall health system performance because primary care, equity, and universal coverage (which address behavioral and social factors) matter more than specialty delivery speed for population health outcomes.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2025-12-01-who-glp1-global-guidelines-obesity]] | Added: 2026-03-16*
|
||||
|
||||
WHO's three-pillar framework for GLP-1 obesity treatment explicitly positions medication as one component within a comprehensive approach requiring healthy diets, physical activity, professional support, and population-level policies. WHO states obesity is a 'societal challenge requiring multisectoral action — not just individual medical treatment.' This institutional positioning from the global health authority confirms that pharmaceutical intervention alone cannot address health outcomes driven by behavioral and social factors.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -309,6 +309,12 @@ PACE is the strongest counter-evidence to attractor state inevitability. Operati
|
|||
|
||||
The BALANCE Model is the first federal policy explicitly designed to test the prevention-first attractor state thesis. By combining GLP-1 access with lifestyle supports and adjusting capitated payment rates, CMS is creating the aligned payment structure that the attractor state requires. The model's success or failure will provide the strongest empirical test yet of whether prevention-first systems can be profitable under risk-bearing arrangements.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2025-12-01-who-glp1-global-guidelines-obesity]] | Added: 2026-03-16*
|
||||
|
||||
WHO's three-pillar framework mirrors the attractor state architecture: (1) creating healthier environments through population-level policies = prevention infrastructure, (2) protecting individuals at high risk = targeted intervention, (3) ensuring access to lifelong person-centered care = continuous monitoring and aligned incentives. The WHO explicitly positions GLP-1s within this comprehensive system rather than as standalone pharmacotherapy, confirming that medication effectiveness depends on embedding within structural prevention infrastructure.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -28,6 +28,12 @@ Post-election vindication translated into sustained product-market fit: monthly
|
|||
|
||||
Polymarket's 2024 election success triggered both state regulatory pushback (36 states filing amicus briefs) and aggressive CFTC defense through Chairman Selig's WSJ op-ed defending exclusive jurisdiction, demonstrating how market validation creates regulatory battlegrounds
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-02-00-prediction-market-jurisdiction-multi-state]] | Added: 2026-03-16*
|
||||
|
||||
Polymarket's 2024 election success has created a regulatory backlash that threatens the entire prediction market industry. As of February 2026, a circuit split has emerged with Tennessee federal court ruling for federal preemption while Nevada, Massachusetts, and Maryland courts uphold state gaming authority. 36 states filed amicus briefs opposing federal preemption, signaling coordinated resistance to prediction market expansion. The vindication of prediction markets as forecasting tools has paradoxically accelerated regulatory crackdown.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -64,6 +64,12 @@ The Investment Company Act adds a separate challenge: if the entity is "primaril
|
|||
|
||||
Since [[Ooki DAO proved that DAOs without legal wrappers face general partnership liability making entity structure a prerequisite for any futarchy-governed vehicle]], entity wrapping is non-negotiable regardless of the securities analysis. The Ooki precedent also creates a useful tension: if governance participation creates liability (Ooki), it should also constitute active management (defeating Howey prong 4).
|
||||
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2026-02-00-prediction-market-jurisdiction-multi-state]] | Added: 2026-03-16*
|
||||
|
||||
The securities law question may be superseded by state gaming law enforcement. Even if futarchy-governed entities pass the Howey test, they may still face state gaming commission enforcement if courts uphold state authority over prediction markets. The Tennessee ruling's broad interpretation—that any 'occurrence of events' qualifies under CEA—would encompass futarchy governance proposals, but Nevada and Massachusetts courts rejected this interpretation. The regulatory viability of futarchy may depend on Supreme Court resolution of the circuit split, not just securities law analysis.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -1,97 +1,6 @@
|
|||
---
|
||||
type: claim
|
||||
domain: internet-finance
|
||||
description: "Dean's List ThailandDAO proposal failed despite 16x projected FDV increase suggesting mechanism friction not valuation disagreement"
|
||||
confidence: experimental
|
||||
source: "Futardio proposal DgXa6gy7nAFFWe8VDkiReQYhqe1JSYQCJWUBV8Mm6aM, 2024-06-22"
|
||||
created: 2026-03-11
|
||||
depends_on: ["MetaDAOs Autocrat program implements futarchy through conditional token markets where proposals create parallel pass and fail universes settled by time-weighted average price over a three-day window", "futarchy adoption faces friction from token price psychology proposal complexity and liquidity requirements"]
|
||||
---
|
||||
|
||||
# Futarchy proposals with favorable economics can fail due to participation friction not market disagreement
|
||||
|
||||
The Dean's List DAO ThailandDAO event promotion proposal failed despite projecting a 16x FDV increase (from $123,263 to $2M+) with only $15K in costs and a 3% TWAP threshold. The proposal's own financial analysis showed the required 3% increase was "small compared to the projected FDV increase" and that the $73.95 per-participant value creation needed was "achievable." Yet the proposal failed to attract sufficient trading volume to pass.
|
||||
|
||||
This failure pattern suggests futarchy markets can reject proposals not because traders disagree with the valuation thesis, but because:
|
||||
|
||||
1. **Liquidity bootstrapping costs exceed expected returns** — Even when a proposal shows positive expected value, the capital and attention required to establish liquid conditional markets may exceed what individual traders can capture
|
||||
|
||||
2. **Proposal complexity creates evaluation friction** — The ThailandDAO proposal included token lockup mechanics, governance power calculations, leaderboard dynamics, and multi-phase rollout plans that increase the cognitive cost of forming a trading position
|
||||
|
||||
3. **Small DAOs face cold-start problems** — With Dean's List FDV at $123K, the absolute dollar amounts at stake may be too small to attract professional traders even when percentage returns are attractive
|
||||
|
||||
This is distinct from [[MetaDAOs futarchy implementation shows limited trading volume in uncontested decisions]] because this proposal was contested (it failed) but still showed low participation. The market didn't actively reject the proposal through heavy fail-side trading — it failed to engage at all.
|
||||
|
||||
## Evidence
|
||||
|
||||
- Dean's List DAO current FDV: $123,263 (2024-06-22)
|
||||
- Proposal budget: $15K total ($10K travel, $5K events)
|
||||
- Required TWAP increase: 3% ($3,698 absolute)
|
||||
- Projected FDV: $2M+ (16x increase)
|
||||
- Proposal status: Failed (2024-06-25)
|
||||
- Trading period: 3 days
|
||||
- Autocrat version: 0.3
|
||||
|
||||
The proposal explicitly calculated that only $73.95 in value creation per participant (50 participants) was needed to hit the 3% threshold, yet failed to attract sufficient trading interest.
|
||||
|
||||
## Challenges
|
||||
|
||||
Single-case evidence limits generalizability. The failure could be specific to:
|
||||
- Dean's List DAO's small size and limited liquidity
|
||||
- The proposal's specific structure (event promotion vs. treasury/technical decisions)
|
||||
- Timing or market conditions during the 3-day trading window
|
||||
|
||||
However, this case provides concrete evidence that [[futarchy adoption faces friction from token price psychology proposal complexity and liquidity requirements]] operates even when the economics appear favorable.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: 2024-08-27-futardio-proposal-fund-the-drift-superteam-earn-creator-competition | Added: 2026-03-15*
|
||||
|
||||
Drift's $8,250 creator competition proposal failed despite having clear upside potential (community engagement, content generation, B.E.T awareness) and minimal downside risk. The proposal offered a structured prize pool across multiple tracks (video, Twitter threads, trade ideas) with established evaluation criteria, yet still failed to generate sufficient market participation. This is a canonical example of participation friction killing an economically sensible proposal.
|
||||
|
||||
|
||||
```markdown
|
||||
### Additional Evidence (extend)
|
||||
*Source: 2024-12-02-futardio-proposal-approve-deans-list-treasury-management | Added: 2026-03-15*
|
||||
*Source: [[2026-03-05-futardio-launch-seyf]] | Added: 2026-03-16*
|
||||
|
||||
Dean's List treasury proposal passed despite requiring active market participation to price a 40 percentage point survival probability improvement. The proposal explicitly calculated that potential FDV increase (5-20%) exceeded the 3% TWAP threshold, suggesting the economics were clearly favorable yet still required formal market validation.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: 2025-01-14-futardio-proposal-should-deans-list-dao-update-the-liquidity-fee-structure | Added: 2026-03-15*
|
||||
|
||||
Dean's List DAO fee structure proposal passed despite requiring traders to actively migrate to new pools and accept 20x higher fees (0.25% to 5%). The proposal explicitly acknowledged potential 20-30% volume decrease but passed anyway, suggesting the market priced the net treasury benefit (~$19k-25k annual growth) as worth the migration friction. This demonstrates that futarchy can approve proposals with significant user friction when the economic benefit is clear.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: 2025-01-14-futardio-proposal-should-deans-list-dao-update-the-liquidity-fee-structure | Added: 2026-03-16*
|
||||
|
||||
Dean's List DAO proposal passed with TWAP threshold requiring only 3% MCAP increase ($307,855 vs $298,889 baseline), suggesting the market viewed the fee increase as marginally positive but not strongly so. The conservative 3% threshold indicates either low participation or weak conviction despite clear revenue projections showing 20x fee increase.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2024-07-18-futardio-proposal-enhancing-the-deans-list-dao-economic-model]] | Added: 2026-03-16*
|
||||
|
||||
The Dean's List proposal passed futarchy governance despite requiring complex multi-step economic modeling (FDV projections, TWAP calculations, sell pressure estimates) that most token holders would not independently verify. The 5.33% projected FDV increase exceeded the 3% TWAP requirement, suggesting the proposal's passage reflected trust in the model rather than independent market validation of the buyback mechanics.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-03-06-futardio-launch-lobsterfutarchy]] | Added: 2026-03-16*
|
||||
|
||||
LobsterFutarchy's failure ($1,183 of $500,000 target) occurred despite proposing infrastructure for a stated market need (agent financial sandboxing) and reasonable economics ($45k/month burn for 12 months). The 99.8% funding shortfall suggests participation friction or credibility gaps rather than market rejection of the concept itself.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2024-12-02-futardio-proposal-approve-deans-list-treasury-management]] | Added: 2026-03-16*
|
||||
|
||||
Dean's List treasury proposal required TWAP > 3% to pass and projected 5-20% FDV increase, well above the threshold. The proposal passed, suggesting that when economic benefits substantially exceed participation thresholds, friction becomes less determinative of outcomes.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
- [[MetaDAOs futarchy implementation shows limited trading volume in uncontested decisions]]
|
||||
- [[futarchy adoption faces friction from token price psychology proposal complexity and liquidity requirements]]
|
||||
- [[MetaDAOs Autocrat program implements futarchy through conditional token markets where proposals create parallel pass and fail universes settled by time-weighted average price over a three-day window]]
|
||||
|
||||
Topics:
|
||||
- domains/internet-finance/_map
|
||||
- core/mechanisms/_map
|
||||
Seyf's near-zero traction ($200 raised) suggests that while participation friction (e.g., proposal complexity) is a factor, market skepticism about team credibility and product-market fit also acts as a distinct, substantive barrier to capital commitment. The AI-native wallet concept attracted essentially no capital despite a detailed roadmap and burn rate projections, indicating a functional rather than purely structural impediment to funding.
|
||||
```
|
||||
|
|
@ -62,22 +62,28 @@ Cloak raised only $1,455 against a $300,000 target (0.5% of target), entering re
|
|||
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2026-03-05-futardio-launch-phonon-studio-ai]] | Added: 2026-03-16*
|
||||
*Source: 2026-03-05-futardio-launch-phonon-studio-ai | Added: 2026-03-16*
|
||||
|
||||
Phonon Studio AI launch failed to reach its $88,888 target and entered refunding status, demonstrating that not all futarchy-governed raises succeed. The project had demonstrable traction (live product, 1000+ songs generated, functional token mechanics) but still failed to attract sufficient capital, suggesting futarchy capital formation success is not uniform across project types or market conditions.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-03-14-futardio-launch-nfaspace]] | Added: 2026-03-16*
|
||||
*Source: 2026-03-14-futardio-launch-nfaspace | Added: 2026-03-16*
|
||||
|
||||
NFA.space launched on futard.io with $125,000 target, demonstrating futarchy-governed fundraising for physical art RWA marketplace. Project has pre-existing traction: 1,895 artists from 79 countries, 2,000+ artworks sold, $150,000 historical revenue, $5,000 MRR, 12.5% repeat purchase rate. This shows futarchy ICO platform attracting projects with demonstrated product-market fit, not just speculative launches.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2024-03-19-futardio-proposal-engage-in-250000-otc-trade-with-colosseum]] | Added: 2026-03-16*
|
||||
*Source: 2024-03-19-futardio-proposal-engage-in-250000-otc-trade-with-colosseum | Added: 2026-03-16*
|
||||
|
||||
Colosseum's $250,000 OTC acquisition of META at market-determined pricing (TWAP if below $850, capped at $850 if below $1,200, void if above $1,200) with 20% immediate unlock and 80% vested over 12 months demonstrates institutional demand for futarchy-governed tokens. The proposal passed and included strategic partnership terms where Colosseum commits to sponsor MetaDAO in the next Solana hackathon DAO track ($50,000-$80,000 prize pool) at no cost, showing how futarchy-governed capital raises can bundle financial and strategic value.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2026-03-09-pineanalytics-x-archive]] | Added: 2026-03-16*
|
||||
|
||||
Q4 2025 data: 8 ICOs raised $25.6M with $390M committed (15.2x oversubscription), 95% refund rate from oversubscription. $300M AMM volume generated $1.5M in fees. These metrics validate both the capital formation efficiency and the market depth supporting futarchy governance.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -0,0 +1,24 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-trap.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 1,
|
||||
"kept": 0,
|
||||
"fixed": 1,
|
||||
"rejected": 1,
|
||||
"fixes_applied": [
|
||||
"glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-trap.md:set_created:2026-03-16"
|
||||
],
|
||||
"rejections": [
|
||||
"glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-trap.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-16"
|
||||
}
|
||||
|
|
@ -0,0 +1,32 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "prediction-market-federal-state-jurisdiction-circuit-split-forces-supreme-court-resolution.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
{
|
||||
"filename": "sports-prediction-markets-trigger-state-gaming-enforcement-while-governance-markets-may-avoid-regulatory-attention.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 2,
|
||||
"kept": 0,
|
||||
"fixed": 2,
|
||||
"rejected": 2,
|
||||
"fixes_applied": [
|
||||
"prediction-market-federal-state-jurisdiction-circuit-split-forces-supreme-court-resolution.md:set_created:2026-03-16",
|
||||
"sports-prediction-markets-trigger-state-gaming-enforcement-while-governance-markets-may-avoid-regulatory-attention.md:set_created:2026-03-16"
|
||||
],
|
||||
"rejections": [
|
||||
"prediction-market-federal-state-jurisdiction-circuit-split-forces-supreme-court-resolution.md:missing_attribution_extractor",
|
||||
"sports-prediction-markets-trigger-state-gaming-enforcement-while-governance-markets-may-avoid-regulatory-attention.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-16"
|
||||
}
|
||||
|
|
@ -7,9 +7,13 @@ date: 2025-07-01
|
|||
domain: health
|
||||
secondary_domains: []
|
||||
format: review
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: medium
|
||||
tags: [glp-1, sarcopenia, muscle-loss, elderly, safety, lean-mass]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-16
|
||||
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -50,3 +54,10 @@ WHY ARCHIVED: Counter-evidence to the GLP-1 benefit thesis — sarcopenia risk m
|
|||
EXTRACTION HINT: The intersection of muscle loss + high discontinuation rates is the key risk — evaluate as a challenge to the cost-savings thesis, not just a clinical side effect
|
||||
|
||||
flagged_for_astra: ["GLP-1-induced muscle loss in elderly has parallels to spaceflight muscle atrophy — different mechanism but similar functional consequences"]
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Natural aging reduces skeletal muscle mass by 12-16% in elderly populations
|
||||
- Sarcopenic obesity prevalence: 10-20% of older adults
|
||||
- No pharmacological solution to GLP-1-induced muscle loss exists yet
|
||||
- Next-generation GLP-1 compounds aim to improve 'quality of weight loss' by preserving muscle (per ADA)
|
||||
|
|
|
|||
|
|
@ -7,9 +7,13 @@ date: 2025-12-01
|
|||
domain: health
|
||||
secondary_domains: []
|
||||
format: policy
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: medium
|
||||
tags: [glp-1, WHO, global-health, obesity, guidelines, equity]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-16
|
||||
enrichments_applied: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -39,3 +43,10 @@ WHO issued conditional recommendations for GLP-1 medicines in obesity treatment
|
|||
PRIMARY CONNECTION: [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]
|
||||
WHY ARCHIVED: WHO's three-pillar framework challenges the pharmacological solution narrative and supports the view that GLP-1s are most effective when embedded in structural prevention infrastructure
|
||||
EXTRACTION HINT: The WHO position supports the BALANCE model's design but questions whether pharmaceutical solutions alone can address the obesity epidemic
|
||||
|
||||
|
||||
## Key Facts
|
||||
- WHO issued conditional (not full) recommendations for GLP-1 medicines in obesity treatment in December 2025
|
||||
- WHO's three-pillar framework: (1) healthier environments through population policies, (2) protecting high-risk individuals, (3) lifelong person-centered care
|
||||
- WHO guideline explicitly states obesity is a societal challenge requiring multisectoral action, not just medical treatment
|
||||
- WHO requires countries to consider local cost-effectiveness, budget impact, and ethical implications before GLP-1 adoption
|
||||
|
|
|
|||
|
|
@ -7,9 +7,13 @@ date: 2026-02-00
|
|||
domain: internet-finance
|
||||
secondary_domains: []
|
||||
format: article
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [prediction-markets, regulation, kalshi, jurisdiction, supreme-court, cftc, state-gaming]
|
||||
processed_by: rio
|
||||
processed_date: 2026-03-16
|
||||
enrichments_applied: ["Polymarket vindicated prediction markets over polling in 2024 US election.md", "futarchy-governed entities are structurally not securities because prediction market participation replaces the concentrated promoter effort that the Howey test requires.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -52,3 +56,13 @@ tags: [prediction-markets, regulation, kalshi, jurisdiction, supreme-court, cftc
|
|||
PRIMARY CONNECTION: [[Polymarket vindicated prediction markets over polling in 2024 US election]]
|
||||
WHY ARCHIVED: Circuit split virtually guarantees SCOTUS involvement. The outcome determines futarchy's regulatory viability. Multiple independent legal analyses converge on this assessment.
|
||||
EXTRACTION HINT: Focus on circuit split as signal for SCOTUS, and the gap between sports prediction market litigation and governance prediction market implications.
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Tennessee federal court ruled pro-Kalshi on February 19, 2026
|
||||
- Nevada state court ruled pro-state, rejecting federal court removal
|
||||
- Massachusetts state court issued preliminary injunction in January 2026
|
||||
- Maryland federal court ruled that CEA preemption doesn't encompass state gambling laws
|
||||
- 36 states filed amicus briefs opposing federal preemption in Fourth Circuit
|
||||
- CFTC Chairman Selig published WSJ op-ed signaling aggressive pro-jurisdiction stance
|
||||
- Sidley Austin reported CFTC signals imminent rulemaking on prediction markets (Feb 2026)
|
||||
|
|
|
|||
|
|
@ -6,9 +6,13 @@ url: "https://www.futard.io/launch/2TK2hDtyNAY2hbV3yHDoVaAPSfaod2sHX7PtWPz8QfmQ"
|
|||
date: 2026-03-05
|
||||
domain: internet-finance
|
||||
format: data
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
tags: [futardio, metadao, futarchy, solana]
|
||||
event_type: launch
|
||||
processed_by: rio
|
||||
processed_date: 2026-03-16
|
||||
enrichments_applied: ["futarchy-proposals-with-favorable-economics-can-fail-due-to-participation-friction-not-market-disagreement.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Launch Details
|
||||
|
|
@ -259,3 +263,12 @@ Our mission is to make capital on Solana programmable through natural language.
|
|||
- Token mint: `GgcMi8LxukwRYS1FZ5W4v2fo8XEAHpscqdQZz26Ymeta`
|
||||
- Version: v0.7
|
||||
- Closed: 2026-03-06
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Seyf launched on futard.io on 2026-03-05 seeking $300,000
|
||||
- Seyf raised only $200 total before entering refunding status
|
||||
- Seyf's pitch deck showed 21-22 month runway with $500k raise target
|
||||
- Seyf planned monthly burn rate of ~$23,000 across team, infrastructure, and marketing
|
||||
- Seyf token mint: GgcMi8LxukwRYS1FZ5W4v2fo8XEAHpscqdQZz26Ymeta
|
||||
- Seyf launch address: 2TK2hDtyNAY2hbV3yHDoVaAPSfaod2sHX7PtWPz8QfmQ
|
||||
|
|
|
|||
|
|
@ -6,7 +6,7 @@ url: https://x.com/PineAnalytics
|
|||
date: 2026-03-09
|
||||
domain: internet-finance
|
||||
format: tweet
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
tags: [metadao, analytics, futardio, decision-markets, governance-data, jupiter]
|
||||
linked_set: metadao-x-landscape-2026-03
|
||||
curator_notes: |
|
||||
|
|
@ -24,6 +24,10 @@ extraction_hints:
|
|||
- "Futardio launch metrics already partially archived — check for new data not in existing archive"
|
||||
- "Cross-reference with existing archives to avoid duplication"
|
||||
priority: medium
|
||||
processed_by: rio
|
||||
processed_date: 2026-03-16
|
||||
enrichments_applied: ["metadao-ico-platform-demonstrates-15x-oversubscription-validating-futarchy-governed-capital-formation.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
# @PineAnalytics X Archive (March 2026)
|
||||
|
|
@ -56,3 +60,13 @@ priority: medium
|
|||
## Noise Filtered Out
|
||||
- Mostly retweets and community engagement
|
||||
- Original content is almost exclusively data-driven — very little opinion
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Jupiter governance proposal: 303 views, 2 comments
|
||||
- MetaDAO futarchy equivalent: $40K volume, 122 trades
|
||||
- bankme token dropped 55% in 45 minutes
|
||||
- No MetaDAO ICO has gone below launch price as of Q4 2025
|
||||
- MetaDAO Q4 2025: 8 ICOs, $25.6M raised, $390M committed
|
||||
- MetaDAO Q4 2025: $300M AMM volume, $1.5M in fees
|
||||
- MetaDAO Q4 2025: 95% refund rate from oversubscription
|
||||
|
|
|
|||
Loading…
Reference in a new issue